<DOC>
	<DOC>NCT02460263</DOC>
	<brief_summary>The purpose of this study is to evaluate the Tablo Hemodialysis System when used In-Center by trained individuals and In-Home by trained Subjects.</brief_summary>
	<brief_title>The EvAluation of TaBlo In-CLinic and In-HOme</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Subject has end stage renal disease (ESRD) adequately treated by maintenance dialysis achieving a Kt/V â‰¥ 1.2 and has been deemed stable for at least three months by his/her treating nephrologist. Subject has a wellfunctioning and stable vascular access that allows a blood flow of at least 300 ml/min. Life expectancy less than 12 months from first study procedure. Subject has had a recent major cardiovascular adverse event within the last 3 months. Subject has New York Class III or IV Congestive Heart Failure, or ejection fraction less than 30%. Subject with fluid overload due to intractable ascites secondary to liver cirrhosis. Subject has uncontrolled blood pressure. Subject is intolerant to heparin. Subject is seroreactive for Hepatitis B Surface Antigen. Subject has an active, lifethreatening, rheumatologic disease. Subject has a history of adverse reactions to dialyzer membrane material. Subject is expected to receive an organ transplant during the course of the study. Subject has a lifethreatening malignancy actively receiving treatment that would prevent successful completion of the study protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>